Blue-Black Nodule

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.

Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.

There are no diagnostic criteria for topical steroid withdrawal but patients describe and discuss it on social media. Study authors tapped a deep source of information.

The key factors predicting stable response to tralokinumab every 4 weeks (vs every 2 weeks) were IGA 0/1 and EASI-75, according to a small post hoc analysis.

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.

Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.